Cogent Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview

Cogent Biosciences

03/05/2024 17:40

* Cogent Biosciences Inc  COGT.OQ   COGT.O  is expected
to show no
change in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Cogent Biosciences Inc
is for
a loss of 52 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Cogent
Biosciences Inc is $17.00​, above​ its last closing price
of $7.29. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.62       -0.56      -0.63     Missed  -11.8
 Sep. 30 2023  -0.50       -0.50      -0.64     Missed  -27.8
 Jan. 1 0001   -0.55       -0.54      -0.59     Missed  -8.3​
 Mar. 31 2023  -0.58       -0.57      -0.54     Beat    5.4
 ​​Dec.        -0.54       -0.52      -0.56     Missed  -8.3
 31 2022                                                
 Sep. 30 2022  -0.53       -0.51      -0.50     Beat    2.6​
 Jun. 30 2022  -0.68       -0.65      -0.71     Missed  -9
 Mar. 31 2022  -0.55       -0.52      -0.68     Missed  -29.5
 This summary was machine generated May 3 at 16:40 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)